No Data
No Data
Earnings Call Summary | KNIGHT THERAPEUTICS INC(KHTRF.US) Q1 2024 Earnings Conference
The following is a summary of the Knight Therapeutics, Inc. (KHTRF) Q1 2024 Earnings Call Transcript:Financial Performance:Knight Therapeutics reported Q1 2024 revenues of over $85 million, a growth o
Knight Therapeutics Inc Price Target Raised to C$5.75/Share From C$5.40 by Stifel Nicolaus
Knight Therapeutics Inc Price Target Raised to C$5.75/Share From C$5.40 by Stifel Nicolaus
Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1
Knight Therapeutics Inc. (GUD.TO) entered Thursday into an exclusive supply and distribution agreement whereby Ironshore Pharmaceuticals & Development, has granted the company the rights to seek regul
Knight Therapeutics Brief: Q1 Net Loss Was $4.546 Million; Revenues Were $86.604 Million
07:35 AM EDT, 05/09/2024 (MT Newswires) -- Knight Therapeutics Brief: Q1 Net loss was $4.546 Million; Revenues were $86.604 Million
Knight Therapeutics Brief: Entering Into Exclusive Supply and Distribution Agreement With Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM In Canada and Latin America
07:33 AM EDT, 05/09/2024 (MT Newswires) -- Knight Therapeutics Brief: Entering into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM In Cana
Knight Therapeutics Reports First Quarter 2024 Results